Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-064733
Filing Date
2025-05-07
Accepted
2025-05-06 18:22:41
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vera-20250331.htm   iXBRL 10-Q 2421065
2 EX-31.1 vera-ex31_1.htm EX-31.1 17564
3 EX-31.2 vera-ex31_2.htm EX-31.2 17533
4 EX-32.1 vera-ex32_1.htm EX-32.1 10721
5 EX-32.2 vera-ex32_2.htm EX-32.2 10938
  Complete submission text file 0000950170-25-064733.txt   8764880

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vera-20250331.xsd EX-101.SCH 1048883
67 EXTRACTED XBRL INSTANCE DOCUMENT vera-20250331_htm.xml XML 1617205
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 1200 BRISBANE CA 94005 650-770-0077
Vera Therapeutics, Inc. (Filer) CIK: 0001831828 (see all company filings)

EIN.: 812744449 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40407 | Film No.: 25918754
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)